In Re: Risperdal Litig., Appeal of: Winter, J. ( 2019 )


Menu:
  •                    [J-52A-2019 and J-52B-2019] [MO: Donohue, J.]
    IN THE SUPREME COURT OF PENNSYLVANIA
    EASTERN DISTRICT
    IN RE: RISPERDAL LITIGATION                  :    No. 22 EAP 2018
    JONATHAN SAKSEK,                             :
    :    Appeal from the Judgment of Superior
    Appellant               :    Court entered on November 13, 2017
    :    at No. 576 EDA 2015 (reargument
    :    denied January 16, 2018) affirming
    v.                             :    the Judgment entered on February
    :    12, 2015 in the Court of Common
    :    Pleas , Philadelphia County, Civil
    JANSSEN PHARMACEUTICALS, INC.,               :    Division at No. 00183 February Term,
    JOHNSON & JOHNSON COMPANY,                   :    2014, No. 296 March Term, 2010.
    JANSSEN RESEARCH AND                         :
    DEVELOPMENT, LLC,                            :    ARGUED: May 16, 2019
    :
    Appellees               :
    IN RE: RISPERDAL LITIGATION                  :    No. 23 EAP 2018
    JOSHUA WINTER,                               :
    :    Appeal from the Judgment of Superior
    Appellant               :    Court entered on November 13, 2017
    :    at No. 590 EDA 2015 (reargument
    :    denied January 16, 2018) affirming
    v.                             :    the Judgment entered on February
    :    10, 2015 in the Court of Common
    :    Pleas , Philadelphia County, Civil
    JANSSEN PHARMACEUTICALS, INC.,               :    Division at No. 01170 March Term,
    JOHNSON & JOHNSON COMPANY,                   :    2014, 296 March Term, 2010.
    JANSSEN RESEARCH AND                         :
    DEVELOPMENT, LLC,                            :    ARGUED: May 16, 2019
    :
    Appellees               :
    CONCURRING OPINION
    JUSTICE BAER                                     DECIDED: NOVEMBER 20, 2019
    I join the majority opinion reversing the Superior Court’s affirmance of the trial
    court’s grant of summary judgment to Janssen Pharmaceuticals, Inc., Johnson & Johnson
    Company, and Janssen Research and Development, LLC (collectively, Janssen). I write
    separately to reiterate my concerns regarding Pennsylvania’s continued adherence to the
    narrow approach to the discovery rule.
    The majority correctly summarizes Pennsylvania jurisprudence regarding the
    discovery rule as utilizing a “narrow approach” involving “inquiry notice,” which tolls the
    statute of limitations until a plaintiff has “actual or constructive knowledge” of the injury
    and awareness that the injury was caused by another. Maj. Op. at 11. This paradigm
    places a greater burden on plaintiffs as compared with the so-called “liberal” approach
    applied by most of our sister states. See Nicolaou v. Martin, 
    195 A.3d 880
    , 892-93 (Pa.
    2018); Wilson v. El-Daief, 
    964 A.2d 354
    , 363-65 (Pa. 2009). The liberal approach looks
    to a plaintiff’s actual or constructive knowledge of the existence of a cause of action, which
    tolls the statute of limitations until a reasonable plaintiff would have knowledge not only
    that an injury was caused by another but that the injury resulted from the negligence of
    another. 
    Id. As I
    have previously expressed, I question whether this Court should align our
    discovery rule jurisprudence with the liberal approach adopted by the majority of our sister
    states.     See 
    Wilson, 964 A.2d at 371-372
    (Baer, J., concurring and dissenting).
    Nevertheless, I recognize that the issue is not before the Court in this case. Accordingly,
    as was true in our recent decision in 
    Nicolaou, 195 A.3d at 892
    n.14, “we await a future
    case” to consider whether to adopt the liberal approach.
    Justice Donohue joins this concurring opinion.
    [J-52A-2019 and J-52B-2019] [MO: Donohue, J.] - 2
    

Document Info

Docket Number: 23 EAP 2018

Filed Date: 11/20/2019

Precedential Status: Precedential

Modified Date: 11/20/2019